Our Services
Medical Information
Helpful Resources
Published on: 5/22/2026
Under specialist ENT care, aspirin desensitization is a structured multi-day protocol that gradually introduces increasing aspirin doses to patients with nasal polyps and aspirin-exacerbated respiratory disease to induce tolerance, reduce polyp recurrence, improve asthma control and lower steroid use while ensuring close monitoring for reactions.
There are several factors to consider from candidate selection, pre-protocol evaluation, step-wise dosing and maintenance regimens to benefits, risks and emergency precautions; see below to understand more.
Aspirin desensitization is a structured medical approach often used for patients with nasal polyps who also have aspirin-exacerbated respiratory disease (AERD). Under the care of an ENT specialist, this protocol can help reduce polyp recurrence, improve breathing, and lessen the need for systemic steroids. Below, you'll find a clear, step-by-step guide to what the process involves, who it's for, and what to expect. Always speak to a qualified ENT doctor about any serious or potentially life-threatening concerns.
Aspirin desensitization is a controlled procedure that gradually introduces aspirin to the body in increasing doses. Over a period of days, the immune system becomes "tolerant," so that the standard daily dose of aspirin can be used safely. For patients with nasal polyps and AERD, this can:
The process must be performed in a specialist clinic with immediate access to emergency treatment.
Not every patient with nasal polyps needs aspirin desensitization. Typical candidates:
Contraindications include active gastrointestinal bleeding, significant kidney disease, or other bleeding risks. Your ENT will review your medical history, current medications, and overall health before recommending desensitization.
Before starting the protocol, your ENT team will complete several preparatory steps:
Comprehensive Evaluation
Asthma Optimization
Informed Consent
Medication Adjustments
Under close medical supervision, most ENT clinics follow a similar stepwise approach over 2–3 days:
Day 1
Day 2 (if needed)
Day 3 (confirmation)
Key points:
Close monitoring is essential to ensure safety:
Minor symptoms are common and expected. If moderate or severe reactions occur (e.g., marked drop in lung function, severe wheezing), the dose is halted, and treatment is given. Most patients complete the protocol within 48–72 hours.
Once desensitization is confirmed, maintaining a daily aspirin dose is crucial. Typical maintenance regimens:
Patients should:
Regular follow-up visits (every 3–6 months) allow your ENT to:
Understanding both sides can help you weigh whether this protocol is right for you.
Benefits
Potential Risks
Your specialist will take steps to minimize risks—such as prescribing a proton pump inhibitor to protect the stomach—and will have emergency treatments on hand during desensitization.
Although mild reactions are part of the protocol, you should seek emergency care or call your doctor if you experience:
For non-emergency symptoms that are concerning you, try Ubie's free Medically Approved AI Symptom Checker to help determine whether your symptoms require immediate attention.
Aspirin desensitization protocol for nasal polyps is a proven strategy to reduce polyp recurrence and improve respiratory health in AERD patients. It requires commitment, close medical supervision, and ongoing maintenance, but the benefits can be life-changing.
Always discuss any serious or life-threatening symptoms with your doctor or seek immediate emergency care. If you're experiencing new or unusual symptoms and aren't sure what to do next, Ubie's Medically Approved LLM Symptom Checker can provide personalized guidance in minutes. Remember, this information is educational and does not replace personalized medical advice. Discuss the risks, benefits, and logistics of aspirin desensitization with your ENT specialist to determine if it's the right path for you.
(References)
* White AA, Stevenson DD. Aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015 Feb;135(2):338-51. doi: 10.1016/j.jaci.2014.07.025. Epub 2014 Sep 11. PMID: 25220268.
* Laidlaw TM, Rank MA, Simon RA, White AA, Tichenor K, Stevenson DD, Lee RU, Cho E. Aspirin Desensitization in Chronic Rhinosinusitis With Nasal Polyps and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2659-2665. doi: 10.1016/j.jaip.2021.03.045. Epub 2021 Mar 27. PMID: 33789178.
* Samaan J, Tieu DD, Benke JR, Hwang PH, Patel ZM. Aspirin-exacerbated respiratory disease in the otolaryngology clinic: current understanding and future directions. Am J Otolaryngol. 2022 May-Jun;43(3):103423. doi: 10.1016/j.ajoto.2022.03.003. Epub 2022 Mar 15. PMID: 35313936.
* Cho E, LaMattina KC, Lee RU, White AA, Stevenson DD, Laidlaw TM. Aspirin desensitization for recurrent nasal polyps and chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2171-2178.e1. doi: 10.1016/j.jaip.2020.01.006. Epub 2020 Feb 21. PMID: 32092576.
* Patel P, Thorp BD, Kuperstock JE, Soler ZM. Chronic Rhinosinusitis with Nasal Polyps and Aspirin-Exacerbated Respiratory Disease: An Evidence-Based Review. Laryngoscope. 2021 Dec;131(12):E3036-E3044. doi: 10.1002/lary.29074. Epub 2021 May 20. PMID: 33900667.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.